Simulations Plus Inc. (SLP)
NASDAQ (NGS) NASDAQ (NGS) Primary 
SET Summary
Simulations Plus: Buying On Long-Term Silico Drug-Development
Simulations Plus is a specialized in silico software-and-services platform. They help with model-informed, non-animal drug development. SLP's services help across discovery, development, and clinical operations. Software remains their main economic driver with higher margins. Services are growing faster and gradually increasing their share of total revenues but have lower margins.
Simulations Plus' Q4 Earnings & Sales Meet Estimates, Fall Y/Y
SLP posts softer fiscal Q4 2025 results but meets full-year goals as cloud, AI and integrated workflows shape its next growth phase.
Simulations Plus, Inc. (SLP) Q4 2025 Earnings Call Transcript
Simulations Plus, Inc. (SLP) Q4 2025 Earnings Call Transcript
Simulations Plus Inc. (SLP) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Simulations Plus Inc. ever had a stock split?
Simulations Plus Inc. Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | Shawn M. O'Connor CEO | NASDAQ (NGS) Exchange | 829214105 CUSIP |
| US Country | 243 Employees | 29 Jul 2024 Last Dividend | 2 Oct 2007 Last Split | 18 Jun 1997 IPO Date |
Overview
Simulations Plus, Inc. is a pioneering company specializing in the development of advanced software tools for drug discovery and development. Utilizing cutting-edge artificial intelligence and machine learning technologies, the company has established a global presence in the field of molecular property simulation and prediction. Operating through two main segments, Software and Services, Simulations Plus caters to a wide range of industries including pharmaceuticals, biotechnology, agrochemical, cosmetics, and food, as well as academic institutions and regulatory agencies. Since its inception in 1996 and headquartered in Lancaster, California, the company has been at the forefront of providing innovative solutions that enhance the efficiency and effectiveness of drug development processes.
Products and Services
- GastroPlus
- DDDPlus & MembranePlus
- Mechanistic and Mathematical Model Based Products
- Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) Predictor
- MedChem Designer
- MonolixSuite
This flagship software simulates the absorption, distribution, metabolism, and elimination of compounds in humans and animals. It also predicts drug interactions, making it a vital tool for pharmaceutical research and development.
Simulations Plus offers these simulation products to further support the study of drug dissolution (DDDPlus) and permeability across membranes (MembranePlus), respectively. These tools are essential for understanding the bioavailability of drugs.
Products like DILIsym, NAFLDsym, ILDsym, RENAsym, IPFsym, and MITOsym utilize mechanistic and mathematical models to simulate and predict various drug-induced effects, including liver injury, nonalcoholic fatty liver disease, interstitial lung disease, renal injury, idiopathic pulmonary fibrosis, and mitochondrial toxicity.
This chemistry-based computer program takes molecular structures as inputs and predicts their ADMET properties, supporting the early stages of drug development and reducing the reliance on physical testing.
A tool designed to assist in the efficient design and modification of medicinal chemicals, facilitating the innovative development of new drug entities through an enhanced understanding of cheminformatics.
Simulations Plus provides MonolixSuite for robust modeling and simulation, enabling users to perform population analyses, clinical trial data analyses, and regulatory submission tasks more efficiently.
Beyond software, Simulations Plus offers a comprehensive range of consulting services aimed at supporting clinical-pharmacological research. This includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services specifically tailored to meet the stringent requirements of regulatory submissions. The company further extends its support with early drug discovery services and insightful consulting services in the domain of quantitative systems pharmacology/quantitative systems toxicology modelling, underscoring its commitment to advancing drug development through innovation and expertise.
